New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
April 25, 2014
11:02 EDTMRK, SNYEMA backs new indication for Sanofi's Gardasil, Merck's Silgard
The Committee for Medicinal Products for Human Use adopted a positive opinion recommending a variation to the terms of the marketing authorization for Sanofi's (SNY) medicinal product Gardasil. The CHMP adopted a new indication of: "Gardasil is a vaccine for use from the age of 9 years for the prevention of: premalignant genital lesions, premalignant anal lesions, cervical cancers and anal cancers causally related to certain oncogenic Human Papillomavirus types and genital wartscausally related to specific HPV types." The CHMP also adopted a positive opinion recommending a variation to the terms of the marketing authorization for Merck Sharp & Dohme's (MRK) Silgard. The CHMP adopted a new indication of: "Silgard is a vaccine for use from the age of 9 years for the prevention of premalignant genital lesions, premalignant anal lesions, cervical cancers and anal cancers causally related to certain oncogenic Human Papillomavirus types and genital warts causally related to specific HPV types."
News For SNY;MRK From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
September 4, 2015
07:20 EDTMRKMerck selloff overdone, says SunTrust
After meeting with four senior Merck executives, SunTrust says that the selloff in the stock over concerns about the company's Januvia franchise are overdone. The firm expects the company's diabetes drugs to generate over $8.5B in revenue in 2020, up from less than $6B currently, through the launch of several new treatments within the next two years. It is upbeat on the outlook for the company's Keytruda cancer treatment and reiterates a $72 price target and Buy rating.
September 3, 2015
16:01 EDTSNYSanofi subsidiary to pay $32.5M to resolve Seprafilm 'criminal liability'
Subscribe for More Information
September 2, 2015
08:04 EDTMRKMerck says FDA approves pediatric indication for Emend capsules
Subscribe for More Information
September 1, 2015
16:17 EDTSNYArdelyx regains NaP2b program from Sanofi
Subscribe for More Information
09:04 EDTMRKMerck reports new analyses from IMPROVE-IT study with Vytorin
Subscribe for More Information
09:01 EDTSNYRegeneron and Sanofi announces Praluent Phase 3 data
Regeneron (REGN) and Sanofi (SNY) announced that, in a new pooled analysis of heterozygous familial hypercholesterolemia patients included in the ODYSSEY clinical trial program, Praluent significantly reduced bad cholesterol, known as low-density lipoprotein cholesterol. This analysis included 1,257 HeFH patients, the largest group of HeFH patients ever studied in a Phase 3 program. At week 24, when the primary efficacy endpoint was assessed, patients treated with Praluent had an average 56 percent greater reduction in LDL-C compared to placebo in both arms. Reductions were observed as early as week 4 and were maintained for the duration of therapy, until week 78.
August 31, 2015
09:07 EDTSNYSanofi, Google Life Sciences to collaborate to improve diabetes health outcomes
Subscribe for More Information
06:35 EDTSNYAlnylam price target raised to $184 from $180 at Piper Jaffray
Piper Jaffray analyst Edward Tenthoff raised his price target for Alnylam Pharmaceuticals (ALNY) to $184 saying the company over the weekend reported positive Phase I data on ALN-PCS showing LDL-cholesterol lowering comparable to Amgen (AMGN) and Sanofi/Regeneron's (REGN) anti-PCSK9 antibodies, but with only quarterly or potentially every 6-month injections. Tenthoff recommends using the recent pullback in shares of Alnylam as a buying opportunity and keeps an Overweight rating on the name.
August 30, 2015
15:50 EDTSNYAlnylam, The Medicines Co. say ALN-PCSsc reduces LDL cholesterol as much as 83%
Subscribe for More Information
12:33 EDTMRKDividend-rich blue chips look attractive amid market volatility, Barron's says
Subscribe for More Information
August 28, 2015
08:01 EDTSNYAmgen pricing for Repatha competitive with Praluent, says Piper Jaffray
After the FDA announced last night that it has approved Amgen's (AMGN) Repatha injection, Piper Jaffray analyst Joshua Schimmer said that the drug's indications seem "generally in line" with those for Praluent from Regeneron (REGN) and Sanofi (SNY). Amgen disclosed an annual WAC of $14,100 for Repatha, which the analyst notes is about $500 per year below Praluent, but Schimmer said that the actual recognized price for each will ultimately be determined by discounting. Schimmer also noted that Amgen said it is working with payers and other purchasers on "innovative pricing programs," though he is uncertain if that means the company is working on a kind of "pay per performance" scheme. The analyst, who believes the market will prove large enough for both treatments, keeps a $200 price target and Overweight rating on Amgen shares.
August 27, 2015
19:14 EDTSNYExpress Scripts to cover both Repatha, Praluent for now, Bloomberg says
Subscribe for More Information
August 26, 2015
08:53 EDTMRKMerck management to meet with SunTrust
Subscribe for More Information
August 23, 2015
12:35 EDTMRKBiotech firms could see 'billions' in sales from new cancer drugs, Barron's says
Subscribe for More Information
August 21, 2015
05:44 EDTMRKStocks with implied volatility movement; DIS MRK
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.
I agree to the theflyonthewall.com disclaimer & terms of use